Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31465140 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL8024923 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL15935504 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL5308716 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL7650398 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL17725159 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL14286742 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL7873800 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL13169264 | 0.98 | TSHR (0.39) | TSHR | |
| SCHEMBL27050968 | 0.98 | TSHR (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590338-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | Aposense Ltd. (IL) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024062489-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | APOSENSE LTD. (IL) | 2024-03-28 | — | — | WO | disclosed |
| CN-110402152-B | Compounds and methods for transmembrane delivery of molecules | 艾博森斯有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2019161213-A1 | TRIALKYNE LINKING AGENTS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | GIFU UNIVERSITY (JP) | 2018-04-05 | — | — | US | disclosed |
| US-9885082-B2 | Embodiments of a probe and method for targeting nucleic acids | UNIVERSITY OF IDAHO (US) | 2018-02-06 | — | — | US | disclosed |
| US-20140220573-A1 | EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING NUCLEIC ACIDS | UNIVERSITY OF IDAHO (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | APOB, TTPA, AOX1 | TSHR 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.